

Multiple Sclerosis: Update Bulletin #1 [February 2018]

<https://marketpublishers.com/r/M7F998E9A50EN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: M7F998E9A50EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche's announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA's potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.

B

Business Questions:

How is Ocrevus expected to be prescribed once launched?

Which agents are anticipated to lose market share as a result of Ocrevus' launch?

How do KOLs view Brabio and how successful is it likely to be?

How do KOLs view Mavenclad, and how successful has the European launch been?

How is Mavenclad currently prescribed?

I would like to order

Product name: Multiple Sclerosis: Update Bulletin #1 [February 2018]

Product link: <https://marketpublishers.com/r/M7F998E9A50EN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7F998E9A50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970